Study: Cannabis to treat symptoms of obsessive-compulsive disorder (OCD)
Researchers have examined the symptoms of obsessive-compulsive disorder (OCD), and found evidence to suggest that the endocannabinoid system (ECS) could play a role in alleviating this highly disabling medical condition. OCD is a complex psychological condition in which patients experience uncontrollable, recurring thoughts (obsessions) and behaviors (compulsions), as well as the urge to repeat actions over and over again. In the United States, 2% to 3% of the adult population is affected. According to a study published in May 2015 in the Archives de la maladie de l'enfant, approximately 4% of children and adolescents have OCD.
The condition is difficult to treat. According to the’International OCD Foundation, The most effective treatment is cognitive-behavioural therapy (CBT) combined with psychiatric drugs such as antidepressants and anti-anxiety medication. However, according to a Harvard Medical School publication dated March 2009, only around 10% fully recover from OCD, and only half improve with treatment.
The study is called« The endocannabinoid system: a new therapeutic target for obsessive-compulsive disorder?». The ECS is involved in regulating our neurotransmitters, the chemical messengers that transmit signals between our nerve cells and other cells in the body, and affects just about all our physical and psychological functions. «We examined the complex workings of the ECS and found evidence from animal and human studies supporting a link between OCD symptoms and the ECS,» said Dr. Reilly Kayser of the New York State Psychiatric Institute (NYSPI).
The study was carried out jointly by NYSPI and New York's Weill Cornell Medical College, which concluded that «Some OCD patients who smoke cannabis anecdotally report that it relieves their symptoms and alleviates anxiety, and several case reports describe patients whose OCD symptoms improved were treated with cannabinoids.» In a pilot study analyzed by the team, 16 patients with severe OCD who had both received therapy and taken Nabilone (a synthetic form of THC acting on the brain's SCS) showed almost twice the reduction in symptoms after four weeks than their counterparts treated with Nabilone alone, or those who had only received cognitive therapy.
-
Cannabis in France4 weeks ago
France Sets July as the Deadline for the Widespread Adoption of Medical Cannabis
-
Cannabis in Europe2 weeks ago
Bosnia and Herzegovina Continues to Roll Out Medical Cannabis Following Its Legalization
-
Cannabis in France2 weeks ago
France Submits the Long-Awaited Decree on the Reimbursement of Medical Cannabis to the Council of State
-
Cannabis in the U.S.2 weeks ago
The DEA Begins Hearings on the Federal Rescheduling of Cannabis
-
Cannabis in Ireland3 weeks ago
The Irish Parliament recommends decriminalizing all drugs
-
Business4 weeks ago
Sanity Group is expanding its presence in Switzerland through a distribution agreement with Astrasana
-
Cannabis in France4 weeks ago
Medical Cannabis in France: What the First Major Study Reveals About Its Actual Impact
-
Cannabis in Switzerland3 weeks ago
St. Gallen, Switzerland, Launches Its 8th Legal Cannabis Pilot Project


You must be logged in to post a comment Login